Afleveringen
-
Chris Sweeney and Rob Jones join Brian and Tom to discuss the relative merits of different ARPIs in prostate cancer.
-
Episode 365: Silke Gillessen and Betrand Tombal join the show to discuss the APCCC meeting and recent publication.
-
Zijn er afleveringen die ontbreken?
-
腎がんの最新の話題〜IO rechallengeと乳頭型腎がんの治療戦略〜
-
前立腺がんの最新の話題〜T cell directed therapyとradioligands〜
-
膀胱がんの最新の話題〜周術期薬物療法とADC〜
-
Betrand Tombal joins Brian and Tom to discuss the historic and current data for AR inhibition with monotherapy with AR blockers.
-
Christopher Cutie from J&J joins the show to discuss the SUNRISE bladder program with the gemcitabine-eluting pretzel across several NMIBC and MIBC states.
-
The RCC panel at Uromigos Live 2024 discusses and debates this topic.
-
Eneste podcast cubrimos los temas de cáncer urotelial discutidos por los Uromigos. El impacto del estudio NIAGARA en utiliar quimio más inmunoterapia enneadyuvancia de Ca urotelial músculo invasor, el uso de pembrolizumab adyuvante después de los datos del estudio AMBASSADOR y la búsqueda de biomarcadores.
-
Tom leads a panel of Shilpa Gupta, Andrea Apolo, Kala Sridhar and Petros Grivas to discuss and debate this timely topic.
-
The Uromigos Live 2024 panel discusses recent radioligand data including PEACE-3
-
Brian hosts a panel at Uromigos Live 2024 in Nashville with Michael Morris, Tanya Dorff and Karen Autio
-
Tom moderates a live panel of Kala Sridhar, Shilpa Gupta, Andrea Apolo and Petros Grivas on the emerging ADC data in bladder cancer
-
Tom and Brian finish discussing ESMO 2024 highlights. Even without a guest Tom still interrupts a lot.
-
Silke joins us to discuss ESMO 2024 highlights, then the birds start singing....
-
Fresh of the Presidential session address, Tom discusses his data with Petros commenting.
-
Uromigos Japan with Yuji, Hiroshi and Nobu is formed and discuss Hiroshi's ESMO data.
-
Arun Azad describes this randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel vs. docetaxel in mHSPC
-
Matt Galsky describes his ESMO 2024 abstract of disitimab vedotiin + pembrlizumab in bladder cancer
- Laat meer zien
